No Data
Statistics on Capital Trend of Stock Connect (T+2) | April 30th
Capital Trend of Hong Kong Stock Connect | April 30
This Insider Has Just Sold Shares In Giant Biogene Holding
GIANT BIOGENE: ANNUAL REPORT 2024
Giant Biotech (02367.HK) has completed the placement of a total of 35 million shares.
On April 28, Gelonghui announced that Giant Biotechnology (02367.HK) has completed the seller's placement on April 23, 2025, while the subscription was completed on April 28, 2025. The additional 35 million shares held by the seller were successfully placed at a placement price of HKD 66.65 per share to no fewer than six professional, institutional and/or individual investors. The Directors conducted all reasonable inquiries and are convinced that these investors, along with their respective ultimate beneficial owners, are independent of the company or its related parties and have no connections with them.
Zhuhai International: The pharmaceutical industry in China is expected to continue the valuation recovery this year, with the market for Innovative Drugs likely to differentiate.
Zhao Yin International published a report indicating that, driven by positive factors such as the export Trade of Innovative Drugs, optimization of domestic procurement policies, the implementation of the Class B medical insurance catalog for Innovative Drugs, the revival of tenders for Medical Devices, and the recovery of domestic demand, the Pharmaceutical Industry is expected to continue experiencing valuation repair in 2025.
Hong Kong Stock Movement | Giant Biotechnology (02367) rises nearly 3%. Institutions indicate that China's restructuring of collagen globalization is accelerating and suggest paying attention to the layout of industry leaders.
Giant Biotechnology (02367) rose nearly 3%, as of the time of writing, it increased by 2.46%, priced at 78.95 Hong Kong dollars, with a transaction amount of 0.103 billion Hong Kong dollars.
